TA664 for liraglutide 3.0 mg) recommend considering GLP-1 agonists for adults with a BMI of 35 kg/m or more (or 32.5 kg/m or more for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds), or a BMI of 30-34.9 kg/m with at least one weight-related comorbidity
Pair any supplement with slow, vet-approved weight goals, high-protein nutrition, and enrichment that encourages natural movement
Back to Journals Journal of Multidisciplinary Healthcare Volume 15 Dietary Supplementations and Depression Authors Thurfah JN, Christine, Bagaskhara PP, Alfian SD , Puspitasari IM Received 26 January 2022 Accepted for publication 2 May 2022 Published 17 May 2022 Volume 2022:15 Pages 11211141 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Scott Fraser Jihan Nurul Thurfah, 1, 2, * Christine, 1, 2, * Petrus Putra Bagaskhara, 1, 2, * Sofa Dewi Alfian, 1, 3 Irma Melyani Puspitasari 1, 3 1 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia
Slightly more (39%) view obesity as a complex chronic disease, compared to the 38% of respondents who identify it as a problem with self-control
The real relationship between NAD+ and GLP-1 is more interesting than that
